Science News

BORDEAUX, France--(BUSINESS WIRE)--FineHeart, a clinical-stage medical technology company specializing in the development of innovative solutions for cardiology, announced today the completion of a €35 million first closing of its Series C financing round. This funding is a key lever for activating European public funding, IPCEI Tech4Cure1, and for establishing its role as a European Active Implantable Medical Devices (AIMDs) leader. In total, FineHeart has secured €83 million in financing comb...

BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the “Board”) has appointed Everett Cunningham as the Company’s next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Execu...

FRAMINGHAM, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV), today provided its preliminary fourth quarter and full year ended December 31, 2025 unaudited global net product revenue results and other operational indicators. “We are extremely pleased with our performance since launching EKTERLY in July, which reflects steady execution, growing utilization, and continued momentum across our business,” said Ben Palleiko, CEO of KalVista. “Fundamental dema...

LANGHORNE, Pa.--(BUSINESS WIRE)--PANTHERx® Rare Pharmacy, the trusted leader and innovator in patient access and support services for personalized rare disease care, and Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced an exclusive distribution agreement for MOLBREEVI. Savara submitted the MOLBREEVI BLA to the U.S. Food and Drug Administration (FDA) in December 2025 for the treatment of autoimmune PAP. Priority Review was req...

RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that advances biopharma innovation, today reported financial results for its first quarter fiscal 2026, ended November 30, 2025. First Quarter 2026 Financial Highlights (as compared to first quarter 2025) Total revenue decreased 3% to $18.4 million Software revenue decreased 17% to $8.9 million, represent...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing and commercializing potential best-in-class medicines for serious and rare diseases, today announced that the Compensation Committee of the company’s Board of Directors, made up entirely of independent directors, approved the grant of non-qualified stock options to purchase an aggregate of 16,650 shares of the company’s common stock to one new employee (the “In...

MENLO PARK, Calif.--(BUSINESS WIRE)--Octave Bioscience, Inc., a commercial stage precision medicine company pioneering biomarker driven solutions for multiple sclerosis, Parkinson’s disease and other neurodegenerative diseases today announced the appointment of Kirk Stockwood as Senior Vice President, Commercial. Mr. Stockwood will spearhead Octave’s commercial strategy as the company scales operations and expands the reach of its precision neurology platform. Mr. Stockwood brings over 20 years...

MIAMI--(BUSINESS WIRE)--A new study from the University of Miami Public Health Policy Lab and the AHF Global Public Health Institute sheds light on why public trust broke down during the COVID-19 pandemic—and what can be done to rebuild it before the next health emergency. Drawing on interviews with government, academic, and private-sector leaders across Florida, the study found that distrust in public health grew due to a lack of transparency, political tensions, and inconsistent communication...

SAN FRANCISCO--(BUSINESS WIRE)--Cytotherapy article shows Ossium’s off-the-shelf organ donor bone marrow enables rapid, consistent alloHCT with strong early clinical data....

LYON, France--(BUSINESS WIRE)--ENYO Pharma (“ENYO”), a clinical-stage biopharmaceutical company developing innovative therapies for kidney diseases, today confirmed positive results from its Phase 2 Alpestria-1 study of vonafexor in patients with Alport syndrome. The data demonstrates that vonafexor, a highly differentiated FXR agonist, produced clinically meaningful improvements on kidney disease progression markers in a high-risk population already receiving standard of care (SoC) therapy. In...